2019年11月19日 · Identification of antigens important for GvL but not GvHD, and vice versa, could impact on donor selection, allow us to track GvL immune responses and begin to specifically harness and strengthen anti-leukemic immune responses against patient AML cells, whilst minimizing the toxicity of GvHD.

Chronic graft versus host disease (cGvHD) is an immunologic phenomenon wherein alloreactive donor T cells aberrantly react against host tissues, leading to damaging inflammatory symptoms. Here, we discuss biological insights into GvL and cGvHD and strategies to balance the prevention of GvHD with maintenance of GvL in modern HSCT.

2022年1月13日 · Allogeneic stem cell transplantation (SCT) is a curative therapy for acute myeloid leukemia (AML). It provides both dose-intensive chemo-radiotherapy and enhancement of...

2015年12月5日 · Associated with GVHD is the well-recognized phenomenon of the graft-versus-leukemia (GVL) effect that results in reduced risk of disease relapse. GVL effects have been observed after treatment for a broad range of hematological malignancies.

2024年12月24日 · With the introduction of post-transplant cyclophosphamide (PTCy), researchers suspect the association between GVHD and GVL is now void. A retrospective study examined the immune effects in adults with AML who underwent HLA-matched SCT with standard calcineurin-based GVHD prophylaxis (n=12,653) and a second cohort of patients who received PTCy ...

2024年4月19日 · 多项回顾性研究评估了相合同胞或无关供者allo-sct 后去除 t 细胞 (tcd) 作为 gvhd 预防对 aml 复发风险的影响。一项大型登记组分析发现，无论 aml 患者移植前的 mrd 状态如何，atg均不会增加 aml 患者的复发率。

2023年2月13日 · The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis has remained debated.

2025年3月30日 · Acute myeloid leukemia (AML) mainly affects elderly people, ... Relapse and death were considered competing events for GVHD outcomes. Survival probabilities, cumulative incidences were reported ...

2023年3月14日 · We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic activity of CD83 CAR T in vivo, without observed myeloablation. Conclusions: CD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of …

The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis has remained debated.